Biotechnology

Uniqure

Uniqure released FY2026 Q1 earnings on May 5 Pre-Market EST, actual revenue USD 3.562 M (forecast USD 5.145 M), actual EPS USD -0.8532 (forecast USD -0.8356)

uniQure Reports Q1 2026 Earnings with Widening Net Loss

uniQure to report Q1 revenue and earnings

UniQure submits market application for Huntington's disease gene therapy in the UK

uniQure Receives Positive Feedback from UK MHRA for Huntington's Disease Gene Therapy AMT-130 and Plans Market Authorization Application

Uniqure to Release FY2026 Q1 Earnings on May 5, Pre-Market EST; Forecast Revenue USD 5.22 M, EPS USD -0.8484

Barclays analyst maintains hold rating on uniQure

uniQure Faces Multiple Securities Class Actions Over AMT-130 Project

Biotech Stocks Experience Collective Volatility in US Pre-Market Trading

Hikaru Nakamura Suffers Major Loss on uniQure Investment

uniQure's stock rises after analyst upgrades and higher target prices

FDA Requires UniQure to Conduct New Placebo-Controlled Study, Shares Plunge

Goldman Sachs Downgrade Leads to 15% Drop in uniQure Stock Price

Uniqure released FY2025 Q4 earnings on March 2 Pre-Market (EST), actual revenue USD 5.568 M (forecast USD 5.676 M), actual EPS USD -0.5946 (forecast USD -0.9127)

Uniqure released FY2025 earnings on March 2 Pre-Market (EST), actual revenue USD 16.1 M (forecast USD 16.29 M), actual EPS USD -3.4602 (forecast USD -3.8912)

uniQure NV's Huntington's Disease Drug AMT-130 Phase I/II Data Not Accepted by FDA

Uniqure to release FY2025 Q4 earnings on March 2, 2026 Pre-Market EST, forecast revenue USD 5.562 M, EPS USD -0.9263

uniQure N.V. Announces Positive Early Trial Results for Gene Therapy AMT-191

uniQure NV Director Robert Gut Disposes of Ordinary Shares

uniQure Updates Gene Therapy Pipeline, Emphasizes Leadership Position

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

Micware

MetaVia

MicroAlgo

QURE

VKTX

SBIO

LABU

IBBQ

Today's whale activity in health care stocks reveals significant trading opportunities. Notable options include bullish call sweeps for HIMS, NVO, VKTX, and ELV, with varying expiration dates and strike prices. REPL shows a bullish put trade, while QURE has a bearish call trade. The data indicates abnormal trading volumes, suggesting potential market movements. Traders are advised to monitor these activities closely for investment strategies.

benzinga_article

Viking Therap

Novo Nordisk AS

ALPS Medical Breakthrough

iShares US Healthcare Providers

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Defiance Leveraged Long +Income HIMS ETF

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

SPDR S&P Health

VG Health

iShares US Medical Devices

SPDR S&P Health Equip

VanEck Biotech ETF

Defiance Daily Target 2X Long NVO ETF

First Trust NYSE Arca Biotech Index Fd

Defiance Daily Target 2X Long HIMS ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Hims & Hers Health

Replimune

Zoetis

Elevance Health

Intuitive Surgical

Centene

CVS Health

10 Health Care Stocks Whale Activity In Today's Session

uniQure (QURE) reported Q1 revenue of $3.56 million and a net loss of $53.54 million, alongside progress on its AMT-130 gene therapy for Huntington's disease. The stock surged 79.84% in a month and 110.34% over the year, suggesting strong momentum. Analysts value the stock at $38.48, indicating it may be undervalued at the current price of $27.66. Future revenue growth hinges on AMT-130's regulatory success and expansion into new treatments. Investors are advised to consider both potential rewards and risks before making decisions.

Simplywall

iShares Biotechnology ETF

A Look At uniQure (QURE) Valuation After Q1 Results And AMT-130 Regulatory Progress

HC Wainwright has forecasted uniQure N.V. (NASDAQ:QURE) to report Q1 2027 earnings of ($0.95) per share, maintaining a "Buy" rating with a target price of $50.00. The consensus estimate for the full year is ($3.60) per share. The company recently reported Q1 earnings of ($0.85) EPS, surpassing estimates. Analysts have varied ratings, with a consensus of "Moderate Buy" and a price target of $42.83. Institutional investors hold 78.83% of the stock, and recent insider selling was reported by CFO Christian Klemt.

Market Beat

What is HC Wainwright's Forecast for uniQure Q1 Earnings?

Uniqure(QURE.US)

10 Health Care Stocks Whale Activity In Today's Session

A Look At uniQure (QURE) Valuation After Q1 Results And AMT-130 Regulatory Progress

What is HC Wainwright's Forecast for uniQure Q1 Earnings?